Verastem (VSTM) Stock Forecast & Price Target

Verastem is supported by a compelling durability story for avutometinib plus defactinib, which in KRAS wild-type low-grade serous ovarian cancer showed an 18% ORR, 13-month median PFS, and 30% of patients staying on therapy for more than a year despite limited treatment options. The broader RAMP 201 and IGCS data also reinforce the current franchise, with weighted median PFS of 22.1 months versus 6.5 months in KRAS-mutant disease and 11.3 months versus 7.7 months in wild-type disease, while the current U.S. label still addresses only the roughly one-third KRAS-mutant population. Add in VS-7375, where 190+ patients are enrolled in TARGET-D 101 and registrational TARGET-D 201, 202, and 203 are being advanced, and the company has multiple catalysts that could expand its addressable market and deepen the long-term commercial opportunity.

Verastem is a late-stage development biopharmaceutical company whose outlook is constrained by the high failure rate of clinical trials, the possibility that its assets or future candidates may not show meaningful efficacy, and the risk that regulatory approval could be delayed or denied. Its valuation framework still relies on FY37 GAAP EPS of $4.31 and an NPV of $14.0/share, which underscores how much of the story depends on distant execution rather than current fundamentals. It also faces intense competition from better-resourced commercial and development-stage rivals, while potential need for additional equity financing adds dilution and financial risk if development costs outpace available capital.